VALANX Biotech appoints Klaus Orlinger as Chief Scientific Officer
Charlie Blackie-Kelly | November 4, 2025 | Appointment | | Antibody-Drug Conjugate, VALANX Biotech, drug development
VALANX Biotech, a company developing novel technology for site-specific protein conjugation in drug discovery, has appointed Klause Orlinger as Chief Scientific Officer.
“Klaus’ expertise in executing on drug development programmes represents a decisive milestone for the company. His knowledge and experience will be instrumental in guiding us as our first antibody-drug-conjugate, VLX-ADC-001, enters candidate selection,” said Michael Lukesch, Founder and CEO at VALANX Biotech.
Prior to joining VALANX, Orlinger held senior roles at HOOKIPA Pharma, including Chief Scientific Officer, Vice President of Research, and Head of Virology. During his tenure, he contributed to the advancement of multiple immuno-oncology and infectious disease candidates from early-stage research through to clinical development, while also supporting the company’s IPO.
At VALANX, Orlinger will oversee the company’s drug development roadmap, including the progression of its GoldenSite conjugation platform and its application in discovering novel therapeutic protein conjugates. The GoldenSite platform combines synthetic biology and click chemistry to enable precise, site-specific protein conjugation, facilitating the creation of next-generation biotherapeutics.
Orlinger added: “Drug-protein-conjugate therapeutics hold great potential for a broad range of diseases but their clinical development is often hampered by limited therapeutic windows. VALANX’s GoldenSite technology is addressing an urgent need to widen limited therapeutic windows and enable the development of best-in-class biotherapeutic drugs.
“I am excited to have joined the team at a pivotal moment for the company to drive the execution of its drug development programmes and to generate more candidate drugs to address unmet medical need in oncology.”
Related Content
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
BioDuro and Silicogenix collaborate to advance non-traditional drug development
BioDuro, a contract research, development and manufacturing organisation, has announced a strategic partnership with small …
